Supplementary Table 1 Correlation between the7th edition UICC and LRstaging systems

mTNM-LR
UICC 7th / N stage / LR=0 / 0<LR≤0.1 / 0.1<LR≤0.4 / 0.1<LR≤0.4 / All
N0 / 140 / 140
N1 / 11 / 7 / 1 / 19
N2 / 2 / 6 / 6 / 14
N3 / 6 / 12 / 18
All / 140 / 13 / 19 / 19 / 191
TNM stage / IA / IB / IIA / IIB / IIIA / IIIB / IIIC / All
IA / 78 / 78
IB / 25 / 25
IIA / 10 / 10
IIB / 19 / 1 / 20
IIIA / 1 / 5 / 2 / 1 / 9
IIIB / 2 / 20 / 7 / 29
IIIC / 4 / 16 / 20
All / 78 / 25 / 10 / 20 / 8 / 26 / 24 / 191

LR: lymph node metastatic ratio, mTNM-LR: modified TNM stage using LR.

Supplementary Table 2 Baseline characteristics of patients with benign disease or gastric cancer

Variables / RGC-B (n=49) / RGC-GC (n=142) / p-value
Age (mean±SD, range) / 63.6±9.8 (35-83) / 58.5±11.3 (30-84) / 0.006
Gender / Male / 45 (92) / 107 (75) / 0.013
Female / 4 (8) / 35 (25)
BMI (kg/m2) (mean±SD, range) / 21.2±2.6 (15.9-28.1) / 21.4±3.1 (15.2-30.4) / 0.617
Comorbidity / No / 26 (53) / 86 (61) / 0.226
Yes / 23 (47) / 56 (39)
Interval (years) (mean±SD, range) / 29.7±9.8 (6-50) / 7.7±7.5 (1-41) / <0.001
Reconstruction / Billroth I / 2 (4) / 37 (26) / 0.001
Billroth II / 47 (96) / 103 (73)
Roux-en-Y / 0 / 2 (1)
Neoadjuvant chemotherapy / No / 48 (98) / 140 (99) / 0.591
Yes / 1 (2) / 2 (1)
Tumor location / Anastomosis site / 35 (71) / 73 (51) / 0.019
Non-anastomosis site / 14 (29) / 69 (49)
Operation type / CTG / 42 (86) / 139 (98) / 0.003
STG / 7 (14) / 3 (2)
Lymphadenectomy / <D2 / 16 (13) / 70 (49) / 0.047
D2 / 33 (87) / 72 (51)
Combined resection / No / 23 (47) / 81 (57) / 0.247
Yes / 26 (53) / 61 (43)
Spleen / 19 / 46 / 0.416
Transverse colon / 5 / 21 / 0.420
Gallbladder / 5 / 8 / 0.216
Liver / 3 / 9 / 0.630
Distal pancreas / 1 / 4 / 0.619
Adrenal gland / 1 / 2 / 0.591
Appendix / 0 / 2 / 0.552
Ovary / 0 / 2 / 0.552
Urinary bladder / 0 / 1 / 0.743
Approach / Open / 47 (96) / 126 (89) / 0.157
Laparoscopic / 0 / 10 (7)
Robot / 2 (4) / 6 (4)
Histology / Differentiated / 20 (41) / 44 (31) / 0.060
Undifferentiated / 26 (53) / 96 (68)
Others / 3 (6) / 2 (1)
Tumor size (cm) (mean±SD, range) / 4.5±3.3 (0.3-15.5) / 3.4±2.3 (0.1-11) / 0.033
T stage* / Mucosa / 11 (22) / 35 (25) / 0.637
Submucosa / 7 (14) / 26 (18)
Proper muscle / 8 (16) / 16 (11)
Subserosa / 5 (10) / 13 (9)
Serosa invasion / 13 (27) / 27 (19)
Adjacent organ invasion / 5 (10) / 25 (18)
N stage* / N0 / 34 (69) / 106 (75) / 0.688
N1 / 6 (12) / 13 (9)
N2 / 3 (6) / 11 (8)
N3a / 4 (8) / 10 (7)
N3b / 2 (4) / 2 (1)
TNM stage* / IA / 18 (37) / 60 (42) / 0.973
IB / 8 (16) / 17 (12)
IIA / 2 (4) / 8 (6)
IIB / 5 (10) / 15 (11)
IIIA / 3 (6) / 6 (4)
IIIB / 8 (16) / 21 (15)
IIIC / 5 (10) / 15 (11)
Positive LN count (mean±SD, range) / 2.1±5.3 (0-28) / 1.5±3.7 (0-26) / 0.354
Retrieved LN count (mean±SD, range) / 26.9±16.2 (4-74) / 10.0±10.5 (0-55) / <0.001
≤15 / 11 (22) / 117 (82) / <0.001
≥16 / 38 (78) / 25 (18)
LR (mean±SD, range) / 0.07±0.16 (0-0.82) / 0.11±0.24 (0-1) / 0.170
Adjuvant chemotherapy / No / 31 (63) / 83 (58) / 0.614
Yes / 18 (37) / 59 (42)
Recurrence / No / 36 (73) / 103 (73) / 0.899
Yes / 13 (27) / 39 (27)

Numbers in parentheses in categorical values are percentages.

*According to the 7th edition UICC classification.

RGC-B: remnant gastric cancer after benign disease, RGC-GC: remnant gastric cancer after gastric cancer, BMI: body mass index, CTG: completion total gastrectomy, STG: subtotal gastrectomy, LN: lymph node, LR: lymph node metastatic ratio.

Bold font indicates statistically significant differences (p-value ≤0.05).